Taken together, downregulation of SETD2 caused a strong anti-proliferative response in primary human AML cells and cell lines expressing various MLL-fusion genes, suggesting a requirement for SETD2 in the oncogenic context of MLL-fusion proteins. The gene discussed is SETD2; the disease is acute myeloid leukemia.